Recombinant Human Thyroid Stimulating Hormone versus Thyroid Hormone Withdrawal for Radioactive Iodine Treatment of Differentiated Thyroid Cancer with Nodal Metastatic Disease
المؤلفون المشاركون
Wolfson, Robert M.
Morrison, Deric
Driedger, Al
Spaic, Tamara
Van Uum, Stanislaus H. M.
Rachinsky, Irina
المصدر
العدد
المجلد 2016، العدد 2016 (31 ديسمبر/كانون الأول 2016)، ص ص. 1-6، 6ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2016-02-09
دولة النشر
مصر
عدد الصفحات
6
التخصصات الرئيسية
الملخص EN
Introduction.
Recombinant human thyroid stimulating hormone (rhTSH) is approved for preparation of thyroid remnant ablation with radioactive iodine (RAI) in low risk patients with well differentiated thyroid cancer (DTC).
We studied the safety and efficacy of rhTSH preparation for RAI treatment of thyroid cancer patients with nodal metastatic disease.
Methods.
A retrospective analysis was performed on 108 patients with histopathologically confirmed nodal metastatic DTC, treated with initial RAI between January 1, 2000, and December 31, 2007.
Within this selected group, 31 and 42 patients were prepared for initial and all subsequent RAI treatments by either thyroid hormone withdrawal (THW) or rhTSH protocols and were followed up for at least 3 years.
Results.
The response to initial treatment, classified as excellent, acceptable, or incomplete, was not different between the rhTSH group (57%, 21%, and 21%, resp.) and the THW group (39%, 13%, and 48%, resp.; P=0.052).
There was no significant difference in the final clinical outcome between the groups.
The rhTSH group received significantly fewer additional doses of RAI than the THW group (P=0.03).
Conclusion.
In patients with nodal-positive DTC, preparation for RAI with rhTSH is a safe and efficacious alternative to THW protocol.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Wolfson, Robert M.& Rachinsky, Irina& Morrison, Deric& Driedger, Al& Spaic, Tamara& Van Uum, Stanislaus H. M.. 2016. Recombinant Human Thyroid Stimulating Hormone versus Thyroid Hormone Withdrawal for Radioactive Iodine Treatment of Differentiated Thyroid Cancer with Nodal Metastatic Disease. Journal of Oncology،Vol. 2016, no. 2016, pp.1-6.
https://search.emarefa.net/detail/BIM-1109709
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Wolfson, Robert M.…[et al.]. Recombinant Human Thyroid Stimulating Hormone versus Thyroid Hormone Withdrawal for Radioactive Iodine Treatment of Differentiated Thyroid Cancer with Nodal Metastatic Disease. Journal of Oncology No. 2016 (2016), pp.1-6.
https://search.emarefa.net/detail/BIM-1109709
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Wolfson, Robert M.& Rachinsky, Irina& Morrison, Deric& Driedger, Al& Spaic, Tamara& Van Uum, Stanislaus H. M.. Recombinant Human Thyroid Stimulating Hormone versus Thyroid Hormone Withdrawal for Radioactive Iodine Treatment of Differentiated Thyroid Cancer with Nodal Metastatic Disease. Journal of Oncology. 2016. Vol. 2016, no. 2016, pp.1-6.
https://search.emarefa.net/detail/BIM-1109709
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1109709
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر